NICE Endorses Natalizumab RRMS Treatment Expans...

By João L. Carapinha

January 9, 2026

NICE Expands Access to Natalizumab RRMS Treatment for Highly Active Cases The National Institute for Health and Care Excellence (NICE) has issued final draft ...
NICE Approves Seven Digital Cardiac Rehabilitation Technologies for Enhanced ...
Advancing EU Health Technology Assessment: Key Priorities in the HTACG Draft ...
Rethinking HEOR Market Access Integration: A Call for Early Engagement Before...
Emblaveo MDR Infections: Evaluating a New Solution for Multidrug-Resistant Gr...
NICE NHS Prioritization: A Strategic Shift to Address Healthcare Challenges
Challenging the Narrative: Pharmaceutical Innovation Funding and Its Complex ...
NICE Endorses Darolutamide Prostate Cancer Treatment for Improved Patient Access
Rethinking Health Technology Assessment: Evolving Economic Evaluations for Fa...
Paving the Way for Digital Health Technologies: NICE’s Bold New Strateg...
NICE Endorses Breakthrough Bladder Cancer Treatment for Enhanced Survival
TAVI Cost-Effectiveness in Brazil: Balancing Coverage Expansion and Economic ...
Evolving Strategies in Type 2 Diabetes Management: NICE Guideline Update 2025